Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02200640
Recruitment Status : Completed
First Posted : July 25, 2014
Last Update Posted : July 25, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The primary aim of the trial is to compare the influence of MICARDIS® (telmisartan 40-80 mg) and COZAAR® (losartan 50-100 mg) in lowering ambulatory diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing interval as measured by ABPM after 8-weeks treatment. Secondary objectives include evaluations of: 1) change from baseline in mean systolic blood pressure (SBP) during the last 6 hours of the 24-hour dosing interval as measured by ABPM, 2) changes from baseline in SBP and DBP during other periods during the 24-hour ABPM profile, 3) changes from baseline in mean seated trough SBP and DBP as measured by manual cuff sphygmomanometer, and 4) responder rates based on both ABPM and trough cuff blood pressure

Condition or disease Intervention/treatment Phase
Hypertension Drug: High dose of Micardis®, once daily Drug: Low dose of Micardis®, once daily Drug: Low dose of COZAAR®, once daily Drug: High dose of COZAAR®, once daily Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 333 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 & 80 mg QD) and COZAAR® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
Study Start Date : March 2000
Actual Primary Completion Date : December 2000

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Low dose of Micardis® Drug: Low dose of Micardis®, once daily
Other Name: Telmisartan

Drug: Placebo
Experimental: High dose of Micardis® Drug: High dose of Micardis®, once daily
Other Name: Telmisartan

Drug: Placebo
Active Comparator: Low dose of COZAAR® Drug: Low dose of COZAAR®, once daily
Other Name: Losartan

Drug: Placebo
Active Comparator: High dose of COZAAR® Drug: High dose of COZAAR®, once daily
Other Name: Losartan

Drug: Placebo



Primary Outcome Measures :
  1. Change from baseline in mean diastolic blood pressure [ Time Frame: Up to 8 weeks after start of treatment ]
    Measured during the last 6 hours of the 24-hour dosing interval using ABPM


Secondary Outcome Measures :
  1. Change from baseline in mean systolic blood pressure [ Time Frame: Up to 8 weeks after start of treatment ]
    Measured during the last 6 hours of the 24-hour dosing interval using ABPM

  2. Changes from baseline in diastolic and systolic blood pressure [ Time Frame: Up to 8 weeks after start of treatment ]
    Measured during other times of the 24-hour ABPM profile (e.g. 24-hour mean, morning mean, daytime mean and nighttime mean)

  3. Changes from baseline in mean seated trough diastolic blood pressure and systolic blood pressure [ Time Frame: Up to 8 weeks after start of treatment ]
    Triplicate measurement in two minute intervals after 5 minutes of rest, in seated position using sphygmomanometer

  4. Assessment of responder rates on ABPM [ Time Frame: Baseline, 8 weeks after start of treatment ]
  5. Assessment of responder rates on trough cuff blood pressure [ Time Frame: Baseline up to 8 weeks after start of treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥ 95 mmHg and ≤ 109 mmHg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP). The manual cuff value is calculated as the mean of three seated measurements taken two minutes apart, after the patient has been seated quietly for 5 minutes
  • A 24-mean DBP of ≥ 85 mmHg at Visit 7 as measured by ABPM
  • Age 18 years or older
  • Ability to stop current antihypertensive therapy without risk to the patient (investigator's discretion)
  • Ability to provide written informed consent

Exclusion Criteria:

  • Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:

    • are not surgically sterile; and/or
    • are nursing
    • are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of ≥ 3-months duration. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
  • Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥ 110 mmHg during any visit of the placebo run-in period
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    • Serum glutamate-pyruvate-transaminase (alanine aminotransferase) or serum glutamate-oxaloacetate-transaminase (aspartate aminotransferase) greater than two times the upper limit of normal
    • Serum creatinine > 2.3 mg/dL
  • Clinically relevant sodium depletion, hyperkalemia, or hypokalemia
  • Uncorrected volume depletion
  • Primary aldosteronism
  • Biliary obstructive disorders
  • Known or suspected secondary hypertension
  • Hereditary fructose intolerance
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
  • Congestive heart failure (NYHA functional class congestive heart failure (CHF) class III-IV)
  • Unstable angina within the past three months
  • Stroke within the past six months
  • Myocardial infarction or cardiac surgery within the past three months
  • Percutaneous transluminal coronary angioplasty (PTCA) within the past three months
  • History of angioedema
  • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
  • Patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an HbA1c ≥ 10%
  • Known drug or alcohol dependency within the past 6 months
  • Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
  • Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 ante meridien (AM)
  • Patients receiving any investigational therapy within one month of signing the informed consent form
  • Known hypersensitivity to any component of the formulations
  • Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02200640     History of Changes
Other Study ID Numbers: 502.343
First Posted: July 25, 2014    Key Record Dates
Last Update Posted: July 25, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Losartan
Telmisartan
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action